Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Choice
100%
Health-related Quality of Life
100%
Etirinotecan Pegol
100%
NKTR-102
100%
Metastatic Breast Cancer
100%
Breast Cancer Outcomes
100%
Locally Recurrent Breast Cancer
100%
Recurrent or Metastatic
100%
Global Health Status
37%
Disease Progression
25%
Physical Function
25%
Gastrointestinal Diseases
25%
Quality of Life Questionnaire
25%
Change from Baseline
25%
Breast Cancer
12%
Liver
12%
Diarrhea
12%
Capecitabine
12%
Taxanes
12%
Cancer Treatment
12%
Brain Metastases
12%
Standard of Care
12%
Anthracyclines
12%
Metastatic Disease
12%
Treatment Effect
12%
Post-randomization
12%
Symptom Score
12%
Dyspnea
12%
Systemic Side Effects
12%
End of Treatment
12%
Patient-completed
12%
Topoisomerase Inhibitors
12%
European Organizations
12%
Median Overall Survival
12%
Specific Quality of Life
12%
Health-related Quality of Life Scores
12%
Quality of Life Measurement
12%
Physical Functioning Scale
12%
Functional Scale
12%
QLQ-BR23
12%
Clinical Decision-making
12%
During Treatment
12%
Promising Therapeutics
12%
Adverse Event Profiles
12%
Clinically Meaningful Benefit
12%
Cancer Quality of Life
12%
Advanced/metastatic Breast Cancer
12%
Nursing and Health Professions
Breast Cancer
100%
Metastatic Breast Cancer
100%
Quality of Life
100%
Etirinotecan Pegol
100%
Health Status
27%
Global Health
27%
Physical Functioning
27%
Gastrointestinal Symptom
18%
Disease Exacerbation
18%
Health Care Quality
9%
Randomization
9%
Malignant Neoplasm
9%
Adverse Event
9%
Overall Survival
9%
Diarrhea
9%
Anthracycline
9%
Dyspnea
9%
Brain Metastasis
9%
Capecitabine
9%
Decision-Making
9%
Side Effect
9%
DNA Topoisomerase
9%
Medicine and Dentistry
Quality of Life
100%
Breast Cancer
100%
Metastatic Breast Cancer
100%
Etirinotecan Pegol
100%
Health Status
27%
Global Health
27%
Disease Exacerbation
18%
Arm
18%
Gastrointestinal Distress
18%
Topoisomerase
9%
Metastatic Carcinoma
9%
Capecitabine
9%
Brain Metastasis
9%
Diarrhea
9%
Clinical Decision Making
9%
Dyspnea
9%
Overall Survival
9%
Cancer Treatment
9%
Anthracycline
9%
Treatment Effect
9%
Side Effect
9%
Adverse Event
9%
Psychology
Quality of Life
100%
Breast Cancer
100%
Decision Making
9%
Health Care Quality
9%